Rafael BJ, Cicero RE, Dibildox MM, Sotres RD, Gutiérrez GR

Language: Spanish
References: 20
Page: 63-67
PDF size: 97.43 Kb.

ABSTRACT

The objective of this study was to compare the safety and efficacy of oral iron sulfate (IS) versus iron hydroxide polymaltose complex (IPC) for the treatment of iron deficiency anemia in infants. Initial evaluation included complete medical history, cell blood count (CBC), reticulocyte count, plasma iron and ferritin levels, total iron-binding capacity and transferrin saturation. Thirty patients were randomly assigned to receive either IS or IPC. The changes in the different studied parameters were similar in both groups, except for the reticulocyte count, which in the IS group, rose significantly faster until the day 10 after treatment but returned to comparable levels after day 30. No adverse events were found in the IPC or IS groups. It can be concluded that oral IPC is as effective as oral IS in the correction of iron-deficiency anemia in infants. The safety and tolerability profile of IPC makes it the oral iron preparation of choice in children.

REFERENCES

1. The World Health Report 1998. Life in the 21 St century. A vision for all. World Health Organization, Geneva. 1998

2. DeMaeyer E, Adiels-Tegman M. The prevalence of anemia in the world. World Health Stat Q 1985; 38: 305.

3. Layrisse M. Deficiencia de hierro en América Latina. Bol Soc Bras Hematol Hemoter 1988; 149: 92.

4. Müller A, Geisser P. Iron pharmacokinetics after administration of ferric-hydroxide-polymaltose complex in rats. Arneim Forsch Drug Res 1984; 34(II) 11: 1560-1569.

5. Hallberg L, Herwerth HG, Vannotti A. Iron Deficiency. Academic Press INC 1970: 558.

6. Jacobs P, Wormald L, Gregory M. Absorption of iron polymaltose and ferrous sulphate in rats and humans. S Afr Med J 1979; 55: 1065.

7. Jacobs P. Oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose. J Med 1984; 15: 367-377.

8. Kaltwasser JP. Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. Arneim/Forsch/Drug Res 1987; 37(1): 122.

9. Baumgartner JA. Overview of clinical studies regarding the safety of iron polymaltose complex. (Toxicity, iron overloading). Vifor files 1997.

10. Andrade J. Tratamento da anemia ferropriva con hidróxido de ferro polimaltosado. ABP supl. Arqueves Brasileiros de Medicina 1992; 66(3): 253.

11. Langstaff RJ, Geisser P, Heil WG, Bowdler MA. Treatment of iron-deficiency anemia: a lower incidence of adverse effects with Ferrum Hausmann than ferrous sulfate. Brit J Clin Res 1993; 4: 191.

12. Schmidt BJ. Comparacao terapeutica entre o sulfato ferrosos o ferro trivalente em forma de complexo de hidroxido ferrico polimatisadona deficiencia organica de ferro. A Folha Medica 1985; 90: 4.

13. Brock C, Curry H, Hanna C, Knipfer M, Taylor L. Adverse effects of iron supplementation: a comparative trial of a wax-matrix iron preparation and conventional ferrous sulfate tablets. Clinical Therapeutics 1985; 7(5): 568-573.

14. Brock C, Curry H. Comparative incidence of side effects of a wax-matrix and a sustained-release iron preparation. Clinical Therapeutics 1985; 7(4): 492-496.

15. Geisser P. In vitro studies on interactions of iron sants and complexes with foodstuffs and medicaments. Drug Res 1990; 40: 754.

16. Preventing iron poisoning in children. FDA Backgrounder 1997.

17. Johnson G, Jacobs P. Bioavailability and the mechanisms of intestinal absorption of iron from ferrous ascorbate and ferric polymaltose in experimental animals. Exp Hematol 1990; 18: 1064.

18. Kreuzer M, Kirchgessner M. Kinetics of Fe (III)-hydroxide-polymaltose supplied orally, intravenously and intramuscularly to rats as obtained by radiotracer techniques. Trace elements in Medicine 1991; 8(1): 43-52.

19. Mackintosh W, Jacobs P. Response in serum ferritin and haemoglobin to iron therapy in blood donors. Am J Hematol 1988; 27: 17.

20. Tuomainen TM, Nyyssönen K, Porkkala-Sarabato E et al. Oral supplementation with ferrous sulfate but not with non-ionic iron polymaltose complex increases the susceptibility of plasma lipoproteins to oxidation. Nutrition Research. In Press.